The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies

Journal of Biomedical Science

Volumn 18, Issue 1, 2011, Pages

  Lu, Shin Hua ^a   Wu, Josephine W ^a   Liu, Hsuan Liang ^a   Zhao, Jian Hua ^b   Liu, Kung Tien ^b   Chuang, Chih Kuang ^a,c,d   Lin, Hsin Yi ^a   Tsai, Wei Bor ^e   Ho, Yih ^f  

^a NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC SYSTEM; DRUG SCREENING; ENZYME ACTIVE SITE; GUNER HENRY SCORE; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; MOLECULAR MODEL; NEUROPROTECTION; PHARMACOPHORE; PRIORITY JOURNAL; SCORING SYSTEM; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; FACTUAL DATABASE; HUMAN; METABOLISM; NERVE CELL; CELL PROTECTION; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; VIRTUAL REALITY;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CHOLINESTERASE INHIBITORS; DATABASES, FACTUAL; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEURONS;

EID: 78651521685     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-18-8     Document Type: Article

References (53)

1. Molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of Alzheimer's disease. J Munoz-Muriedas JM Lop (Pubitemid 39242908)
2. Pathways of ligand clearance in acetylcholinesterase by multiple copy sampling. D Van Belle L De Maria G Iurcu SJ Wodak, J Mol Biol 2000 298 705 726 10.1006/jmbi.2000.3698 10788331
3. Induced-fit or preexisting equilibrium dynamics? Lessons from protein crystallography and MD simulations on acetylcholinesterase and implications for structure-based drug design. Y Xu JP Colletier H Jiang I Silman JL Sussman M Weik, Protein Sci 2008 17 601 605 10.1110/ps.083453808 18359854 (Pubitemid 351480853)
4. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. I Silman JL Sussman, Curr Opin Pharmacol 2005 5 293 302 10.1016/j.coph.2005.01.014 15907917 (Pubitemid 40674253)
5. Acetylcholinesterase accelerates assembly of amyloid - peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. NC Inestrosa A Alvarez CA Perez RD Moreno M Vicente C Linker OI Casanueva C Soto J Garrido, Neuron 1996 16 881 891 10.1016/S0896-6273(00)80108-7 8608006 (Pubitemid 26124065)
6. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. NC Inestrosa MC Dinamarca A Alvarez, FEBS J 2008 275 625 632 10.1111/j.1742-4658.2007.06238.x 18205831 (Pubitemid 351160969)
7. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. T Rees PI Hammond H Soreq S Younkin S Brimijoin, Neurobiol Aging 2003 24 777 787 10.1016/S0197-4580(02)00230-0 12927760 (Pubitemid 37288853)
8. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. TM Rees A Berson EH Sklan L Younkin S Younkin S Brimijoin H Soreq, Curr Alzheimer Res 2005 2 291 300 10.2174/1567205054367847 15974894 (Pubitemid 40980187)
9. A structural motif of acetylcholinesterase that promotes amyloid -peptide fibril formation. GV De Ferrari MA Canales I Shin LM Weiner I Silman NC Inestrosa, Biochemistry 2001 40 10447 10457 10.1021/bi0101392 11523986 (Pubitemid 32816655)
10. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. M Harel I Schalk L Ehret-Sabatier F Bouet M Goeldner C Hirth PH Axelsen I Silman JL Sussman, Proc Natl Acad Sci USA 1993 90 9031 9035 10.1073/pnas.90.19.9031 8415649 (Pubitemid 23306445)
11. Three-dimensional structures of acetylcholinesterase and of its complexes with anticholinesterase agents. I Silman M Harel P Axelsen M Raves JL Sussman, Biochem Soc Trans 1994 22 745 749 7821677 (Pubitemid 24272803)
12. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. M Harel DM Quinn HK Nair I Silman JL Sussman, J Am Chem Soc 1996 118 2340 2346 10.1021/ja952232h (Pubitemid 26124248)
13. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. HM Greenblatt G Kryger T Lewis I Silman JL Sussman, FEBS Lett 1999 463 321 326 10.1016/S0014-5793(99)01637-3 10606746 (Pubitemid 30001943)
14. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. G Kryger I Silman JL Sussman, J Physiol Paris 1998 92 191 194 10.1016/S0928-4257(98)80008-9 9789806 (Pubitemid 29050932)
15. A modular treatment of molecular traffic through the active site of cholinesterase. SA Botti CE Felder S Lifson JL Sussman I Silman, Biophys J 1999 77 2430 2450 10.1016/S0006-3495(99)77080-3 10545346 (Pubitemid 29519491)
16. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. JL Sussman M Harel F Frolow C Oefner A Goldman L Toker I Silman, Science 1991 253 872 879 10.1126/science.1678899 1678899 (Pubitemid 21917225)
17. Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket. A Ordentlich D Barak C Kronman Y Flashner M Leitner Y Segall N Ariel S Cohen B Velan A Shafferman, J Biol Chem 1993 268 17083 17095 8349597 (Pubitemid 23236937)
18. Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. D Barak C Kronman A Ordentlich N Ariel A Bromberg D Marcus A Lazar B Velan A Shafferman, J Biol Chem 1994 269 6296 6305 8119978 (Pubitemid 24190997)
19. The Protein Data Bank. HM Berman J Westbrook Z Feng G Gilliland TN Bhat H Weissig IN Shindyalov PE Bourne, Nucleic Acids Res 2000 28 235 242 10.1093/nar/28.1.235 10592235 (Pubitemid 30047768)
20. The price of innovation: new estimates of drug development costs. JA DiMasi RW Hansen HG Grabowski, J Health Econ 2003 22 151 185 10.1016/S0167-6296(02)00126-1 12606142 (Pubitemid 36279392)
21. Cheminformatics analysis of organic substituents: identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups. P Ertl, J Chem Inf Comput Sci 2003 43 374 380 12653499
22. Virtual screening-an overview. WP Walters MT Stahl MA Murcko, Drug Discov Today 1998 3 160 178 10.1016/S1359-6446(97)01163-X
23. Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. PJ Lakshmi BV Kumar RS Nayana MS Mohan R Bolligarla SK Das MU Bhanu AK Kondapi M Ravikumar, Bioorg Med Chem 2009 17 6040 6047 10.1016/j.bmc.2009.06.069 19631549
24. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. D Wei X Jiang L Zhou J Chen Z Chen C He K Yang Y Liu J Pei L Lai, J Med Chem 2008 51 7882 7888 10.1021/jm8010096 19090779
25. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. ML Bolognesi R Banzi M Bartolini A Cavalli A Tarozzi V Andrisano A Minarini M Rosini V Tumiatti C Bergamini, J Med Chem 2007 50 4882 4897 10.1021/jm070559a 17850125 (Pubitemid 47525472)
26. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. ML Bolognesi A Cavalli L Valgimigli M Bartolini M Rosini V Andrisano M Recanatini C Melchiorre, J Med Chem 2007 50 6446 6449 10.1021/jm701225u 18047264 (Pubitemid 350309081)
27. Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[-(benzylmethylamino)alkoxy]xanthen-9-ones. L Piazzi F Belluti A Bisi S Gobbi S Rizzo M Bartolini V Andrisano M Recanatini A Rampa, Bioorg Med Chem 2007 15 575 585 10.1016/j.bmc.2006.09.026 17008100 (Pubitemid 44738548)
28. Extensive SAR and Computational Studies of 3-{4-[(Benzylmethylamino) methyl]phenyl}-6,7-dimethoxy-2H- 2-chromenone (AP2238) Derivatives. L Piazzi A Cavalli F Belluti A Bisi S Gobbi S Rizzo M Bartolini V Andrisano M Recanatini A Rampa, J Med Chem 2007 50 4250 4254 10.1021/jm070100g 17655212 (Pubitemid 47301756)
29. Novel Donepezil-Based Inhibitors of Acetyl- and Butyrylcholinesterase and Acetylcholinesterase- Induced -Amyloid Aggregation. P Camps X Formosa C Galdeano T Go mez D Mun oz-Torrero M Scarpellini E Viayna A Badia MV Clos A Camins, J Med Chem 2008 51 3588 3598 10.1021/jm8001313 18517184 (Pubitemid 351875014)
30. Pyrano[3,2-c]quinoline-6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and -Amyloid-Directed Anti-Alzheimer Compounds. P Camps X Formosa C Galdeano D Munoz-Torrero L Ramirez E Gomez N Isambert R Lavilla A Badia MV Clos, J Med Chem 2009 52 5365 5379 10.1021/jm900859q 19663388
31. Benzofuran-Based Hybrid Compounds for the Inhibition of Cholinesterase Activity, Amyloid Aggregation, and A Neurotoxicity. S Rizzo C Riviére L Piazzi A Bisi S Gobbi M Bartolini V Andrisano F Morroni A Tarozzi JP Monti, J Med Chem 2008 51 2883 2886 10.1021/jm8002747 18419109 (Pubitemid 351706016)
32. Inhibition of Acetylcholinesterase, -Amyloid Aggregation, and NMDA Receptors in Alzheimer's Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush. M Rosini E Simoni M Bartolini A Cavalli L Ceccarini N Pascu DW McClymont A Tarozzi ML Bolognesi A Minarini, J Med Chem 2008 51 4381 4384 10.1021/jm800577j 18605718
33. Structure-Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 4. Further Investigation on the Inner Spacer. V Tumiatti A Milelli A Minarini M Rosini ML Bolognesi M Micco V Andrisano M Bartolini F Mancini M Recanatini, J Med Chem 2008 51 7308 7312 10.1021/jm8009684 18954037
34. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. BR Brooks RE Bruccoleri BD Olafson, J Comput Chem 1983 4 187 217 10.1002/jcc.540040211
35. HypoGen: An automated system for generating 3D predictive pharmacophore models. H Li J Sutter RD Hoffmann, Pharmacophore perception, development, and use in drug design, IUL Biotechnology Series La Jolla, CA: International University Line, Güner OF, 2000 171 189
36. Effect of Variable Weights and Tolerances on Predictive Model Generation. J Sutter O Güner RD Hoffmann H Li M Waldman, Pharmacophore perception, development, and use in drug design, IUL Biotechnology Series La Jolla, CA: International University Line, Güner OF, 2000 501 511
37. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Y Kurogi OF Güner, Curr Med Chem 2001 8 1035 1055 11472240 (Pubitemid 32633658)
38. In Methods and principles in Medicinal Chemistry, Pharmacophores and Pharmacophores Searches. K Poptodorov T Luu RD Hoffmann, Germany: Wiley-VCH:Weinheim, Langer T, Hoffmann RD, 2006 2 17 47
39. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. S Liu EA Neidhardt TH Grossman T Ocain J Clardy, Structure 2000 8 25 33 10.1016/S0969-2126(00)00077-0 10673429 (Pubitemid 30051339)
40. Metric for analyzing hit lists and pharmacophores. OF Güner DR Henry, Pharmacophore perception, development, and use in drug design, IUL Biotechnology Series La Jolla, CA: International University Line, Güner OF, 2000 191 212
41. Strategies for database mining and pharmacophore development, 1st. OF Güner M Waldman RD Hoffmann JH Kim, Pharmacophore perception, development, and use in drug design, IUL Biotechnology Series La Jolla: International University Line, Güner OF, 2000 213 236
42. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. OO Clement CM Freeman RW Hartmann VD Handratta TS Vasaitis AM Brodie VC Njar, J Med Chem 2003 46 2345 2351 10.1021/jm020576u 12773039 (Pubitemid 36637919)
43. Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors. S Butini G Campiani M Borriello S Gemma A Panico M Persico B Catalanotti S Ros M Brindisi M Agnusdei, et al. J Med Chem 2008 51 3154 3170 10.1021/jm701253t 18479118 (Pubitemid 351821876)
44. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. G Campiani C Fattorusso S Butini A Gaeta M Agnusdei S Gemma M Persico B Catalanotti L Savini V Nacci E Novellino HW Holloway NH Greig T Belinskaya JM Fedorko A Saxena, J Med Chem 2005 48 1919 1929 10.1021/jm049510k 15771436 (Pubitemid 40396322)
45. Multi-target-directed ligands to combat neurodegenerative diseases. A Cavalli ML Bolognesi A Minarini M Rosini V Tumiatti M Recanatini C Melchiorre, J Med Chem 2008 51 347 372 10.1021/jm7009364 18181565 (Pubitemid 351252260)
46. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. MI Rodriguez-Franco MI Fernandez-Bachiller C Perez B Hernandez-Ledesma B Bartolome, J Med Chem 2006 49 459 462 10.1021/jm050746d 16420031 (Pubitemid 43157478)
47. Benchmarking sets for molecular docking. N Huang BK Shoichet JJ Irwin, J Med Chem 2006 49 6789 6801 10.1021/jm0608356 17154509 (Pubitemid 44749746)
48. Selection criteria for drug-like compounds. I Muegge, Med Res Rev 2003 23 302 321 10.1002/med.10041 12647312 (Pubitemid 36457537)
49. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. CA Lipinski F Lombardo BW Dominy PJ Feeney, Adv Drug Deliv Rev 2001 46 3 26 10.1016/S0169-409X(00) 00129-0 11259830 (Pubitemid 33653411)
50. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. G Kryger M Harel K Giles L Toker B Velan A Lazar C Kronman D Barak N Ariel A Shafferman I Silman JL Sussman, Acta Crystallogr Sect D-Biol Crystallogr 2000 56 1385 1394 10.1107/S0907444900010659
51. High throughput docking for library design and library prioritization. DJ Diller KM Merz, Proteins: Struct Funct Bioinf 2001 43 113 124 10.1002/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO;2-T
52. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. MG Marcu A Chadli I Bouhouche M Catelli LM Neckers, J Biol Chem 2000 275 37181 37186 10.1074/jbc.M003701200 10945979 (Pubitemid 32002137)
53. Molecular dynamics of acetylcholinesterase. T Shen K Tai RH Henchman JA McCammon, Accounts Chem Res 2002 35 332 340 10.1021/ar010025i